DUSSELDORF, Germany, May 23 The company endedthe financial year 2007 with a positive result. In 2007 Gerresheimer achievedsales of EUR957.7m and operating earnings (adjusted EBITDA) of EUR181.6m. Forthe first quarter of the current financial year 2008, the company reports asales increase of 18.2% to EUR 239.1m, with a 20.4% increase in operatingearnings (adjusted EBITDA) to EUR 43.0m.
"In the past year we have expanded our regional presence with consistentfocus on the high-profit business in specialty products for the pharmaceuticsand life-science industry. We intend to continue this successful strategy in2008," says Dr. Axel Herberg, CEO of Gerresheimer AG.
At the Shareholders' Meeting in Dusseldorf today, Dr. Herberg confirmedthe positive prospects for 2008. In the coming year the company aims toachieve sales growth of 14%-16% and an Adjusted EBITDA margin in excess of19%.
By a large majority the shareholders of Gerresheimer AG approved theactions of the Management Board and Supervisory Board for the financial year2007 and a dividend payment of EUR0.40 per share. In the first year after itsstock-exchange flotation Gerresheimer is therefore already distributing a sumof EUR12.6m to its shareholders.
By a large majority the shareholders also authorised the Management Boardof Gerresheimer AG to issue warrant-linked bonds and convertible bonds up tothe value of EUR500m in conjunction with the creation of contingent capital.They thereby supported the continued expansion course of the Dusseldorfsupplier to the pharma and life-science industry.
A large number of shareholders and shareholder representatives attendedthe first Shareholders' Meeting of Gerresheimer AG after the IPO in June2007, so 59% of the capital stock was represented at the Shareholders'Meeting.
Gerresheimer facts and figures
Gerresheimer employs more than 10,800 people in 41 production locationsin Europe, America and Asia. In the financial year 2007, worldwide salestotalled EUR 957.7m. The product portfolio ranges from pharmaceutical vialsmade of glass and plastic to complex drug delivery systems for the pharma andlife-science industry. It includes sterile syringes, inhalers and othersystem-based approaches for safe dosage and application of medicines. TheGroup has a leading position in markets which are characterised by hightechnical and regulatory barriers.Contact Press: Burkhard Lingenberg, Director Corporate PR & Marketing, Telephone +49-211-6181-250, Telefax +49-211-6181-241, e-mail email@example.com . Contact Investor Relations: Anke Linnartz, Director Corporate Investor Relations, Telephone +49-211-6181-314, Telefax +49-211-6181-121, e-mail firstname.lastname@example.org .
SOURCE Gerresheimer AG